The manufacturers that market transcatheter aortic valve replacement (TAVR) systems in the US support the US Centers for Medicare and Medicaid Services' (CMS) new Medicare National Coverage Determination (NCD) for TAVR. They believe the new policy will help bring TAVR to patients that cannot access the procedure under the existing policy, created in 2012.
Manufacturers Support CMS’ New TAVR National Coverage Decision
CMS has completed its new national Medicare Coverage with Evidence Development policy for transcatheter aortic valve replacement. The final decision memo largely maintains the recommendations from the draft version released in March, including more flexible criteria for centers establishing TAVR programs, while emphasizing the importance of the interdisciplinary heart team for decision-making about valve replacement.
